GlassScriptPhysician profile
Tina Kauderer
NPI 1366763468
$5,062.31
in general payments reported to CMS, 2019-2025
23 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $751 · 2023: $1,035 · 2024: $1,398 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,993.41 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,216.45 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,073.61 | 2021-2025 | |
| Axsome Therapeutics, INC. | $646.59 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $462.12 | 2024-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $390.77 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $296.97 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $216.06 | 2024-2025 | Spravato, Invega Sustenna |
| Novo Nordisk INC | $137.77 | 2022-2025 | Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $118.05 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $113.43 | 2025 | Fanapt |
| Lundbeck LLC | $85.00 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $73.97 | 2022 | |
| Sunovion Pharmaceuticals INC. | $72.34 | 2021 | |
| Nevro Corp. | $21.37 | 2022 | |
| Dexcom, INC. | $18.72 | 2025 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $18.13 | 2022 | |
| Merck Sharp & Dohme LLC | $17.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.79 | 2022 | |
| Shield Therapeutics INC | $15.65 | 2024 | |
| Lilly USA, LLC | $15.46 | 2024 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $13.83 | 2023 | |
| Paratek Pharmaceuticals, INC. | $11.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Kauderer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.